Clinical Trials Logo

Septo-Optic Dysplasia clinical trials

View clinical trials related to Septo-Optic Dysplasia.

Filter by:
  • None
  • Page 1

NCT ID: NCT06262152 Recruiting - Blindness Clinical Trials

Sleep Profile of Patients With Septo-optic Dysplasia

Start date: December 20, 2023
Phase:
Study type: Observational

The aim of this study is to evaluate sleep of patients with septo-optic dysplasia compared to patients with an isolated disorder of peripheral visual system and patients with corpus callosum agenesis since both visus defict and agenesis of corpus callosum might be present SOD but associated to other features / structural and functional anomalies. Included patients and their caregivers will be asked to compile standardize sleep questionnaires and a sleep screening through an interview will be scheduled. Patients will be asked to wear an actigraph on their non-dominant hand wrist for 7 days.

NCT ID: NCT05717855 Completed - Clinical trials for Cavum Septum Pellucidum

Screening of Septo-optic Dysplasia During a Fetal Examination at 16-20 Weeks of Gestation

Start date: September 21, 2020
Phase: N/A
Study type: Interventional

Evaluation of prenatal optic chiasm (OC) is important for the differential diagnosis of septo-optic dysplasia (SOD), which is a congenital optic disc anomaly, and the absence of the cavum septum pellucidum (CSP). Septo-optic dysplasia is associated with a wide range of neurological abnormalities, including hypoplasia of the visual pathways, CSP agenesis, and developmental delay.

NCT ID: NCT02558829 Completed - Clinical trials for Growth Hormone Deficiency With Pituitary Anomalies

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

Start date: December 3, 2015
Phase: Phase 3
Study type: Interventional

The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial. The trial will include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of healthy control subjects.

NCT ID: NCT00140413 Completed - Clinical trials for Growth Hormone Deficiency

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

Start date: December 2004
Phase: Phase 4
Study type: Interventional

Hypotheses: 1. The prevalence of endocrinopathies, and growth hormone (GH) deficiency in particular, among young children diagnosed with optic nerve hypoplasia (ONH) is higher than is commonly thought. 2. Early treatment of children with ONH and GH-deficiency can prevent adverse outcomes. Aims: 1. Determine the prevalence and types of endocrinopathies in children diagnosed with ONH. 2. Correlate endocrine outcome with radiographic, ocular, and developmental findings in children with ONH. 3. Examine the effect of GH treatment on growth and obesity in children with ONH, GH-deficiency, and either subnormal or normal growth compared to children with ONH that are not GH-deficient. 4. Compare growth outcomes between children with isolated GH-deficiency and those with multiple hormone deficiencies.